
EU Ministers Press Commission on Delayed REACH Revision Amid Industry and Environmental Demands
EU Member States urge the Commission to accelerate the REACH revision, citing urgent health, environmental, and industry competitiveness needs.


The European Commission has recently revised Regulation (EC) No 1907/2006, extending the use of bis(2-ethylhexyl) phthalate (DEHP) in medical devices. Originally, the use of DEHP was to be subject to authorisation requirements after May 2025, but the new regulation, EC 2023/2482, issued on November 13, 2023, postpones this deadline. This amendment aligns with the extended transitional periods for medical device regulations (EU) 2017/745 and (EU) 2017/746, reflecting the need for a gradual shift to DEHP-free medical devices.
This regulatory change aims to maintain public health and patient safety standards while addressing the limited capacity of notified bodies and the challenges companies face in transitioning to DEHP-free alternatives. The Commission emphasises the importance of ensuring a high level of protection for health services and patients, without compromising current quality and safety requirements.
The changes are the result of a positive engagement between industry and regulators on the impact of regulation on market sectors. Working together enables better regulation to protect human health and the environment.
For years, DEHP has been one of the most commonly used plasticisers in medical devices including the following applications:
Earlier this year, MedTech Europe welcomed the positive opinion of the REACH Committee of extending the latest application date and the sunset date to the new transition period of the sector-specific Medical Devices Regulation.
Use of DEHP in medical devices within the European Economic Area (EEA) will necessitate authorisation post the extended sunset date. This delay offers manufacturers using DEHP an opportunity to innovate and integrate DEHP-free alternatives into their devices. Should the new deadlines not provide sufficient leeway, EEA-based manufacturers are advised to seek authorisation before the newly set application date.
Keep updated with Signal for the latest developments and expert analysis on this and other pressing medical device matters as they unfold.
Foresight continuously tracks 1000s of sources and maps updates to your portfolio:




EU Member States urge the Commission to accelerate the REACH revision, citing urgent health, environmental, and industry competitiveness needs.

The EU has classified DBDPE as a substance of very high concern (SVHC) due to vPvB properties, affecting manufacturers and downstream users of flame retardants.

REACH fees rise from 5 November 2025 while SMEs remain exempt. New EU rules require ex ante SME verification from February 2027.
Subscribe to Foresight Weekly and get the latest insights on regulatory changes affecting chemical compliance.
Free forever. Unsubscribe anytime.
Read by professionals at